Disclosed is a composition comprising at least two HLA-binding peptides selected from: (a) at least one of a peptide comprising an epitope according to SEQ ID NO: 23, or a peptide comprising an epitope according to SEQ ID NO: 23 fused to the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain； and (b) at least one of a peptide comprising an epitope selected from the group consisting of: SEQ ID NO: 1 to SEQ ID NO: 11, SEQ ID NO: 13 to SEQ ID NO: 22, and SEQ ID NO: 24 to SEQ ID NO: 42, wherein said peptides of (a) and (b) have an overall length of between 8 and 30 amino acids, wherein the sequences are as defined in the complete specification. Further disclosed is the use of said composition for the preparation of a medicament for the treatment of prostate cancer.
